The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
Rosenkranz, Stephan; Channick, Richard; Chin, Kelly M.; Jenner, Bartosz; Gaine, Sean; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Hoeper, Marius M.; McLaughlin, Vallerie V.; Du Roure, Camille; Rubin, Lewis J.; Sitbon, Olivier; Tapson, Victor; Lang, Irene M.
2022-01
Citation
Rosenkranz, Stephan; Channick, Richard; Chin, Kelly M.; Jenner, Bartosz; Gaine, Sean; Galiè, Nazzareno ; Ghofrani, Hossein-Ardeschir ; Hoeper, Marius M.; McLaughlin, Vallerie V.; Du Roure, Camille; Rubin, Lewis J.; Sitbon, Olivier; Tapson, Victor; Lang, Irene M. (2022). "The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study." European Journal of Heart Failure 24(1): 205-214.
Abstract
AimsThe number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH- targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study.Methods and resultsRandomized patients (n = 1156) were classified using three methods: (i) by subgroups defined according to previously published comorbidity count and restrictive haemodynamic criteria: Subgroup A (<3 comorbidities and haemodynamic criteria met; n = 962) and Subgroup B (- ¥3 comorbidities and/or haemodynamic criteria not met; n = 144); comorbidities included body mass index - ¥30- kg/m2, essential hypertension, diabetes, history of coronary artery disease; (ii) by number of comorbidities, with addition of atrial fibrillation (0, 1, 2, 3, 4, or 5); (iii) by presence of individual comorbidities. Selexipag to placebo hazard ratios (HR) and 95% confidence intervals (CI) for morbidity/mortality (primary composite endpoint) were estimated using Cox regression adjusting selexipag effect for baseline covariates. Approximately half of the patients in GRIPHON (n = 584; 50.5%) had comorbidities. Selexipag reduced the risk of a morbidity/mortality event compared with placebo in both Subgroup A (HR 0.66, 95% CI 0.53, 0.82) and Subgroup B (HR 0.50, 95% CI 0.26, 0.96), with no evidence of an inconsistent treatment effect between subgroups (interaction p = 0.432). Consistent results were observed in analyses by number and by specific type of comorbidity.ConclusionSelexipag reduces the risk of a morbidity/mortality event vs. placebo irrespective of patient comorbidity status, suggesting that comorbidity status does not influence the treatment effect of selexipag.Selexipag reduced the risk of morbidity/mortality events in patients with pulmonary arterial hypertension (PAH) independently of the patients’ comorbidity status. CI, confidence interval; LVEDP, left ventricular end- diastolic pressure; PAWP, pulmonary arterial wedge pressure; RCT, randomized controlled trial.Publisher
John Wiley & Sons, Ltd.
ISSN
1388-9842 1879-0844
Other DOIs
Types
Article
Metadata
Show full item recordCollections
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.